Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies-Reference-Cited by-同舟云学术

Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies

Published:2017-08 Issue: Volume:81 Page:135-137
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Bernard-Tessier Alice,Jeanville Priscilla,Champiat Stéphane,Lazarovici Julien,Voisin Anne-Laure,Mateus Christine,Lambotte Olivier,Annereau Maxime,Michot Jean-Marie^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference8 articles.

1. Immune-related adverse events with immune checkpoint blockade: a comprehensive review;Michot;Eur J Cancer Oxf Engl 1990,2016

2. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper;Champiat;Ann Oncol,2016

3. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival;Delyon;Ann Oncol,2013

4. Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy;Moreira;Immunotherapy,2017

5. From the Uppsala monitoring centre: a review of viewpoint part 1 and part 2;Hugman;Drug Saf,2005

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review of T Helper 2-Type Inflammatory Diseases Following Immune Checkpoint Inhibitor Treatment;Biomedicines;2024-08-19

2. PD-1 negatively regulates helper T cell differentiation into Th2;2024-07-26

3. Acute Eosinophilic Pneumonia Induced by Immune Checkpoint Inhibitor and Anti-TIGIT Therapy;AM J CASE REP;2024

4. Advanced non-small cell lung cancer patient with a complete response and allergic immune-related adverse events by combined immunotherapy, including anti-CTLA-4 and anti-PD-1 antibodies: A case report;Current Problems in Cancer: Case Reports;2024-06

5. Eosinophilic granulocytes as a potential prognostic marker for cancer progression and therapeutic response in malignant melanoma;Frontiers in Oncology;2024-05-02